Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results

Femasys (NASDAQ:FEMY) released its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports. The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.66 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Femasys Price Performance

FEMY stock opened at $1.34 on Friday. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The stock has a market cap of $30.57 million, a PE ratio of -1.65 and a beta of -2.85. Femasys has a 12 month low of $0.86 and a 12 month high of $1.84. The company has a 50-day moving average price of $1.40 and a 200 day moving average price of $1.22.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price target on shares of Femasys from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, March 19th.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.